Tyra Biosciences Inc
NASDAQ:TYRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Suzhou TFC Optical Communication Co Ltd
SZSE:300394
|
CN |
Tyra Biosciences Inc
Total Equity
Tyra Biosciences Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tyra Biosciences Inc
NASDAQ:TYRA
|
Total Equity
$259.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
-$3.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$22.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$8.7B
|
CAGR 3-Years
33%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$18.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
17%
|
CAGR 10-Years
35%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$31.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
23%
|
CAGR 10-Years
24%
|
|
Tyra Biosciences Inc
Glance View
Tyra Biosciences, Inc. develops therapies for oncology and cancer diseases. The company is headquartered in Carlsbad, California and currently employs 25 full-time employees. The company went IPO on 2021-09-15. The firm is focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The firm uses its proprietary SNAP platform, which enables refinement of structural design through iterative molecular SNAPshots. The firm is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR), which are altered in approximately 7% of all cancers. Its lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. In addition, it has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase (RET), and FGFR4-related cancers.
See Also
What is Tyra Biosciences Inc's Total Equity?
Total Equity
259.2m
USD
Based on the financial report for Dec 31, 2025, Tyra Biosciences Inc's Total Equity amounts to 259.2m USD.
What is Tyra Biosciences Inc's Total Equity growth rate?
Total Equity CAGR 3Y
0%
Over the last year, the Total Equity growth was -24%.
